SAS Output

21-JUL-2017 18:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1330 433 187 92 30 9 07/08/2014 437 222
            1330 433 187 92 30 9      
 
    2 Y 17 S1400G   28 28 28 16 2 1      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        3 S1400B   54 11 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 14 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   580 333 145 70 22 7      
            1018 386 173 86 24 8      
 
    3 P 10 S1400I   7 7 1 1 1 0      
        18 S1400G   6 6 6 3 1 0      
        8 S1400B   1 1 0 0 0 0 07/08/2014    
            14 14 7 4 2 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014 4 5
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 3 2 2 0 0 0 07/31/2014    
            3 2 2 0 0 0      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 23 23 23 18 5 1 03/03/2017 434 216
            23 23 23 18 5 1      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 350 103 64 22 10 2 1 12/29/2015 437 221
        2 Nivolumab   108 72 29 13 4 1      
            211 136 51 23 6 2      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 Y 1 AFATINIB + CETUXIMAB 605 64 36 23 15 3 0 05/07/2015 227 92
        2 AFATINIB   65 38 25 16 7 2      
            129 74 48 31 10 2      
 
  S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 1 T 1 Trametinib + Docetaxel 53 37 37 25 16 0 0 10/05/2016 194 92
            37 37 25 16 0 0      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 Y 5 RT+Pac+Carbo+blinded drug 132 13 13 10 4 1 0 01/24/2013 144 51
        6 RT+Pac+Carbo+blinded drug   12 12 9 4 0 0      
            25 25 19 8 1 0      
 
    2 Y 8 Pac + Carbo + blinded drug 132 12 12 11 9 4 0 01/24/2013    
            12 12 11 9 4 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   24 14 10 4 2 0 04/01/2015   253
            24 14 10 4 2 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   330 183 105 52 32 1 12/16/2014 461 253
            330 183 105 52 32 1      
 
  C140503-NSCL, Lobect v Sublobar resect 1 E Total Registrations   17 3 0 0 0 0 07/02/2008 104 53
            17 3 0 0 0 0      
 
    2 E Total Registrations   27 2 0 0 0 0 07/02/2008    
            27 2 0 0 0 0      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   51 1 1 1 1 0 05/14/2008 244 114
            51 1 1 1 1 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   4 2 1 1 1 0 02/29/2016 465 252
            4 2 1 1 1 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   3 3 2 2 2 0 10/20/2016 324 137
            3 3 2 2 2 0      
 
    2 E Total Registrations   3 3 2 2 2 0 10/20/2016    
            3 3 2 2 2 0      
 
  R1306-NSCLC,Adv,ALK/EGFR,TargetAgents 1 E Total Registrations   8 0 0 0 0 0 03/12/2014 157 69
            8 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   336 185 107 53 30 1 12/16/2014 461 253
            336 185 107 53 30 1      
 
  C30607-NSCL,Adv Main Sunitinib v Placbo 1 E Total Registrations   2 0 0 0 0 0 09/25/2013    
            2 0 0 0 0 0      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   14 14 8 4 0 0 08/03/2016 443 234
            14 14 8 4 0 0